Genmab A/S
CSE:GMAB
Genmab A/S
Total Liabilities
Genmab A/S
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Total Liabilities
kr9.1B
|
CAGR 3-Years
55%
|
CAGR 5-Years
53%
|
CAGR 10-Years
27%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Liabilities
kr888.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
20%
|
CAGR 10-Years
10%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Liabilities
€1.3B
|
CAGR 3-Years
86%
|
CAGR 5-Years
74%
|
CAGR 10-Years
58%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Liabilities
kr3B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
17%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Total Liabilities
kr28.2m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
13%
|
|
|
Saniona AB
STO:SANION
|
Total Liabilities
kr107.9m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
21%
|
CAGR 10-Years
32%
|
|
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
What is Genmab A/S's Total Liabilities?
Total Liabilities
9.1B
DKK
Based on the financial report for Dec 31, 2024, Genmab A/S's Total Liabilities amounts to 9.1B DKK.
What is Genmab A/S's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
27%
Over the last year, the Total Liabilities growth was 148%. The average annual Total Liabilities growth rates for Genmab A/S have been 55% over the past three years , 53% over the past five years , and 27% over the past ten years .
You don't have any saved screeners yet